SCHEMBL6414840

SCHEMBL6414840

O=C1NC(CCN2CCC(Cc3cc(F)ccc3Br)CC2)CCN1C1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 15/20 0.43
HTR1A P08908 13/20 0.43
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6417692 0.93 SLC6A4 (0.43) SLC6A4HTR1ARAB9A
SCHEMBL6409983 0.90 SLC6A4 (0.41) SLC6A4HTR1ARAB9A
SCHEMBL6416533 0.89 HTR1A (0.43) SLC6A4HTR1A
SCHEMBL6419233 0.86 HTR1A (0.56) SLC6A4HTR1A
SCHEMBL6614311 0.85 SLC6A4 (0.42) SLC6A4HTR1A
SCHEMBL6416137 0.85 HTR1A (0.49) SLC6A4HTR1A
SCHEMBL6411520 0.85 SLC6A4 (0.41) SLC6A4HTR1ARAB9A
SCHEMBL6418391 0.84 HTR1A (0.50) SLC6A4HTR1A
SCHEMBL6412539 0.81 SLC6A4 (0.46) SLC6A4HTR1A
SCHEMBL6418986 0.81 HTR1A (0.43) SLC6A4HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050065140-A1 Serotonine reuptake inhibitor SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2005-03-24 US disclosed
EP-1466901-A1 SEROTONINE REUPTAKE INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065140-A1 Serotonine reuptake inhibitor HTR1A, SLC6A4, SLC6A2 SLC6A4 2/4885HTR1A 1/4885RAB9A 1141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.